NASDAQ:HALO Halozyme Therapeutics (HALO) Stock Price, News & Analysis $59.26 +0.02 (+0.03%) (As of 09/10/2024 ET) Add Compare Share Share Today's Range$58.59▼$59.8450-Day Range$51.30▼$64.4252-Week Range$32.83▼$65.53Volume764,982 shsAverage Volume1.26 million shsMarket Capitalization$7.51 billionP/E Ratio24.49Dividend YieldN/APrice Target$59.44 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Halozyme Therapeutics alerts: Email Address Halozyme Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.78 Rating ScoreUpside/Downside0.3% Upside$59.44 Price TargetShort InterestBearish7.72% of Float Sold ShortDividend StrengthN/ASustainability-1.12Upright™ Environmental ScoreNews Sentiment0.91Based on 10 Articles This WeekInsider TradingSelling Shares$3.59 M Sold Last QuarterProj. Earnings Growth22.43%From $3.70 to $4.53 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.61 out of 5 starsMedical Sector74th out of 900 stocksBiological Products, Except Diagnostic Industry6th out of 154 stocks 2.4 Analyst's Opinion Consensus RatingHalozyme Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageHalozyme Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Halozyme Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.72% of the float of Halozyme Therapeutics has been sold short.Short Interest Ratio / Days to CoverHalozyme Therapeutics has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Halozyme Therapeutics has recently increased by 8.04%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldHalozyme Therapeutics does not currently pay a dividend.Dividend GrowthHalozyme Therapeutics does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHalozyme Therapeutics has received a 65.83% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Biopharmaceuticals" and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Halozyme Therapeutics is -1.12. Previous Next 2.7 News and Social Media Coverage News SentimentHalozyme Therapeutics has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Halozyme Therapeutics this week, compared to 6 articles on an average week.Search InterestOnly 20 people have searched for HALO on MarketBeat in the last 30 days. This is a decrease of -9% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Halozyme Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Halozyme Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,585,084.00 in company stock.Percentage Held by InsidersOnly 2.40% of the stock of Halozyme Therapeutics is held by insiders.Percentage Held by Institutions97.79% of the stock of Halozyme Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Halozyme Therapeutics' insider trading history. Previous Next 4.4 Earnings and Valuation Earnings GrowthEarnings for Halozyme Therapeutics are expected to grow by 22.43% in the coming year, from $3.70 to $4.53 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Halozyme Therapeutics is 24.49, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 124.87.Price to Earnings Ratio vs. SectorThe P/E ratio of Halozyme Therapeutics is 24.49, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 122.64.Price to Earnings Growth RatioHalozyme Therapeutics has a PEG Ratio of 0.57. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioHalozyme Therapeutics has a P/B Ratio of 94.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Halozyme Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets[NOTICE] Your Download Link BelowIf you still haven't downloaded our brand new report: "The Last Retirement Stock You'll Ever Need"...Download "The Last Retirement Stock You'll Ever Need" About Halozyme Therapeutics Stock (NASDAQ:HALO)Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.Read More HALO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HALO Stock News HeadlinesAugust 22, 2024 | insidertrades.comInsider Selling: Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Sells 10,000 Shares of StockAugust 16, 2024 | insidertrades.comInsider Selling: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Sells 9,881 Shares of StockSeptember 11, 2024 | Monument Traders Alliance (Ad)Join Training: Target 1,000% with One $0.99 election tradeMillionaire Trader Nate Bear is hosting a FREE TRAINING TODAY, where he'll demonstrate how his unique trading strategy can help smart Americans are using to target massive trading profits during the 2024 elections. This is the same trader who famously turned $37k into $2.7 million in just four years, right from his Georgia home.August 15, 2024 | insidertrades.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Director Matthew L. Posard Sells 10,000 SharesSeptember 10 at 1:27 AM | americanbankingnews.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Consensus Recommendation of "Moderate Buy" from AnalystsSeptember 4, 2024 | msn.comJust A Glitch? Netflix, Apple Lead Breakout Stocks Hitting A SnagSeptember 4, 2024 | americanbankingnews.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Short Interest Up 8.0% in AugustAugust 28, 2024 | prnewswire.comHalozyme to Present at Upcoming Investor ConferencesSeptember 11, 2024 | Monument Traders Alliance (Ad)Join Training: Target 1,000% with One $0.99 election tradeMillionaire Trader Nate Bear is hosting a FREE TRAINING TODAY, where he'll demonstrate how his unique trading strategy can help smart Americans are using to target massive trading profits during the 2024 elections. This is the same trader who famously turned $37k into $2.7 million in just four years, right from his Georgia home.August 18, 2024 | msn.comQuestor: This biotech firm is profiting from an overlooked area of healthcareAugust 15, 2024 | msn.comBreakout Watch: Medical Stock In Buy Range, Notches All-Time HighAugust 15, 2024 | finance.yahoo.comInsider Sale: Director Matthew Posard Sells 29,881 Shares of Halozyme Therapeutics Inc (HALO)August 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Lexeo Therapeutics Amid Anticipated Catalysts and Solid FinancialsAugust 9, 2024 | markets.businessinsider.comHalozyme: Hold Rating Maintained Amidst Solid Q2 Performance and Future UncertaintiesAugust 9, 2024 | msn.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Q2 2024 Earnings Call TranscriptAugust 8, 2024 | msn.comHow These Two Lesser-Known Biotech Names Obliterated Sales ExpectationsAugust 6, 2024 | seekingalpha.comHalozyme Therapeutics, Inc. 2024 Q2 - Results - Earnings Call PresentationAugust 6, 2024 | msn.comHalozyme And Ligand — Two Leading Biotechs — Smash Quarterly ForecastsSee More Headlines Receive HALO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/10/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:HALO CUSIP40637H10 CIK1159036 Webwww.halozyme.com Phone858-794-8889Fax858-704-8311Employees390Year Founded1998Price Target and Rating Average Stock Price Target$59.44 High Stock Price Target$71.00 Low Stock Price Target$49.00 Potential Upside/Downside+0.3%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$2.42 Trailing P/E Ratio24.49 Forward P/E Ratio16.02 P/E Growth0.57Net Income$281.59 million Net Margins38.62% Pretax Margin47.72% Return on Equity195.80% Return on Assets21.07% Debt Debt-to-Equity Ratio5.19 Current Ratio7.41 Quick Ratio6.21 Sales & Book Value Annual Sales$829.25 million Price / Sales9.05 Cash Flow$3.18 per share Price / Cash Flow18.63 Book Value$0.63 per share Price / Book94.06Miscellaneous Outstanding Shares126,680,000Free Float124,219,000Market Cap$7.51 billion OptionableOptionable Beta1.28 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Helen I. Torley M.B. Ch. B. (Age 61)M.R.C.P., President, CEO & Director Comp: $1.82MMs. Nicole LaBrosse (Age 41)Senior VP & CFO Comp: $849.36kDr. Michael J. LaBarre Ph.D. (Age 60)Senior VP & CTO Comp: $843.89kMr. Mark Snyder Esq.Senior VP & Chief Legal OfficerMs. Cortney Caudill M.B.A.Chief Operations OfficerMs. Tram BuiHead of Investor Relations & Corporate CommunicationsMs. Amy Marinne FoxChief Human Resources OfficerMr. Gary GroteChief Commercial OfficerDr. Christopher Wahl M.B.A.M.D., Chief Business OfficerMore ExecutivesKey CompetitorsMomenta PharmaceuticalsNASDAQ:MNTAChina Biologic ProductsNASDAQ:CBPOIovance BiotherapeuticsNASDAQ:IOVATwist BioscienceNASDAQ:TWSTRelay TherapeuticsNASDAQ:RLAYView All CompetitorsInsiders & InstitutionsSanctuary Advisors LLCBought 20,528 shares on 9/5/2024Ownership: 0.016%Michael J LabarreSold 10,000 sharesTotal: $617,500.00 ($61.75/share)Truist Financial CorpSold 16,876 shares on 8/21/2024Ownership: 0.066%Chase Investment Counsel CorpBought 91,337 shares on 8/19/2024Ownership: 0.072%Susquehanna International Group LLPSold 500 shares on 8/16/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions HALO Stock Analysis - Frequently Asked Questions How have HALO shares performed this year? Halozyme Therapeutics' stock was trading at $36.96 at the beginning of 2024. Since then, HALO stock has increased by 60.3% and is now trading at $59.26. View the best growth stocks for 2024 here. How were Halozyme Therapeutics' earnings last quarter? Halozyme Therapeutics, Inc. (NASDAQ:HALO) posted its quarterly earnings results on Tuesday, August, 6th. The biopharmaceutical company reported $0.91 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.73 by $0.18. The business's quarterly revenue was up 4.7% on a year-over-year basis. What is Helen Torley's approval rating as Halozyme Therapeutics' CEO? 12 employees have rated Halozyme Therapeutics Chief Executive Officer Helen Torley on Glassdoor.com. Helen Torley has an approval rating of 75% among the company's employees. Does Halozyme Therapeutics have any subsidiaries? The following companies are subsidiaries of Halozyme Therapeutics: Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH. Who are Halozyme Therapeutics' major shareholders? Halozyme Therapeutics' top institutional shareholders include TD Asset Management Inc (1.86%), Dimensional Fund Advisors LP (1.49%), Epoch Investment Partners Inc. (1.13%) and Thrivent Financial for Lutherans (0.74%). Insiders that own company stock include Helen Torley, Michael J Labarre, Matthew L Posard, Jeffrey William Henderson, James M Daly, Nicole Labrosse and Connie Matsui. View institutional ownership trends. How do I buy shares of Halozyme Therapeutics? Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Halozyme Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Halozyme Therapeutics investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD) and Athabasca Oil (ATH). This page (NASDAQ:HALO) was last updated on 9/11/2024 by MarketBeat.com Staff From Our PartnersFREE TRAINING TODAY ➡️ How to profit from 2024 electionEarlier this year, Millionaire Trader Nate Bear of Monument Traders Alliance went live in front of thousands o...Monument Traders Alliance | SponsoredHow to grow a small trading account into a $100k? Why is Warren Buffett dumping stocks? Billionaires like Warren Buffett, Tim Cook, and Jeff Bezos are offloa...Timothy Sykes | SponsoredKamala's Plan to Bankrupt America—What You Need to KnowWhat if Kamala Wins? The 3 Words That Will Change Everything The same team that predicted Biden’s downfall ...Banyan Hill Publishing | SponsoredWarning For Nvidia HoldersHow The Boeing Disasters Could Hit Nvidia Investors You may have heard about Boeing planes falling apart mi...Stansberry Research | SponsoredWall St. Icon: Looming Financial Tsunami will Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event will hit the American...InvestorPlace | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredYour Crypto Future is at StakeWhat if I told you that bananas could make you a millionaire? No, this isn't a joke – I'm talking about the...Crypto 101 Media | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Halozyme Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.